NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









VesiCURE Therapeutics

VesiCURE Therapeutics

Private
SuzhouHealthcare & Life Scienceshttps://vesicure.com/

Last Round

Angel

Sep 17, 2021

Momentum

Top 25%

of companies Caplight tracks

Company Overview

VesiCURE Therapeutics is a biotechnology company that researches and develops exosome innovative drugs and drug delivery platforms.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine

Business Model

B2B

Customer Profile

Revenue Share, Services & Consulting

AI Layer

Non-AI

Keywords

exosome drug deliveryengineered exosomesextracellular vesiclesdrug delivery platformsiRNA deliverytargeted drug deliveryRNA therapeuticsKRAS targetingundruggable targetsnanomedicineoncology therapeuticsnucleic acid therapyinflammatory diseasesbiopharma

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

VesiCURE Therapeutics Comparables

Compare VesiCURE Therapeutics with similar companies based on industry and business-model similarity.

VesiCURE Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
TheraXyte BioScience
87%
Carmine Therapeutics
83%
Carus Bio
77%

VesiCURE Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
AngelSep 17, 2021

Key People

Founding team and executive leadership

Ke Xu

Founder, Chairman And CEO

Founding Team

VesiCURE Therapeutics Investors

Notable investors and investment history

VesiCURE Therapeutics investors
InvestorRounds
BioTrack CapitalAngel
Legend StarAngel
YuanBio Venture CapitalAngel
Northern Light Venture CapitalAngel

Market signals

Structured signals derived from secondary market and firmographic data.

  • May 20, 2026

    Monthly visitors grew 394% MoM, reaching 1.8K.

  • Jan 22, 2026

    Monthly visitors increased 34% MoM.

VesiCURE Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

VesiCURE Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about VesiCURE Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersSuzhou
Employee Range1
Year Founded2021
Last FundingSep 17, 2021

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.